Intravitreal triamcinolone acetonide for pseudophakic cystoid macular edema.
OBJECTIVE
To report the clinical outcome of patients undergoing intravitreal injection of triamcinolone acetonide as treatment of long-standing cystoid macular edema after phacoemulsification.


METHODS
Prospective clinical interventional cases series studies.


METHODS
The study included five patients suffering from cystoid macular edema after cataract surgery. They received an intravitreal injection of 25-mg crystalline triamcinolone acetonide transconjunctivally with topical anesthesia.


RESULTS
In the follow-up period of 6.6 +/- 4.1 months, visual acuity increased from 0.26 +/- 0.13 to a mean maximal visual acuity of 0.60 +/- 0.19. For all patients, visual acuity improved during the follow-up by at least 0.20. Two (40%) patients developed intraocular pressure values higher than 21 mm Hg, which could be controlled by topical antiglaucomatous treatment.


CONCLUSIONS
Intravitreal triamcinolone acetonide may be a therapeutic option for long-standing cystoid macular edema after cataract surgery.
Jonas
Jost B
JB
Department of Ophthalmology, Faculty for Clinical Medicine Mannheim, Ruprecht-Karls-University, Heidelberg, Germany. Jost.Janos@ma.augen.uni-heidelberg.de
Kreissig
Ingrid
I
Degenring
Robert F
RF
D000368:Aged; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007267:Injections / Q000379:methods; D007429:Intraocular Pressure; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology; D018918:Phacoemulsification / Q000009:adverse effects; D011446:Prospective Studies; D019591:Pseudophakia / Q000188:drug therapy*; D016896:Treatment Outcome; D014222:Triamcinolone Acetonide / Q000627:therapeutic use*; D014792:Visual Acuity; D014822:Vitreous Body / Q000187:drug effects*
D005938:Glucocorticoids; D014222:Triamcinolone Acetonide